Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Dasatinib, although relatively specific for ABL, BCR-ABL and the SFKs, it possesses a broad-spectrum of inhibition of kinases including Kit, PDGFR, EphA receptors and several others (Hantschel et al., 2008).”
From Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab (2011) · cites this paper as Hantschel et al., 2008
In the citing paper
“We recognize that while dasatinib primarily targets SFKs and BCR-ABL, it also inhibits other kinases including c-KIT, PDGFRβ, EPHA2, among others [41].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [41]
Citations
Cites
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488 · cited 1×
“In addition to these cases of so-called secondary imatinib resistance, approximately 15% of patients with chronic phase CML do not achieve a complete cytogenetic response on imatinib at the standard dose of 400 mg [4].”
BackgroundGlobal Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317 · cited 1×
“DDR1 is emerging as an important player in immunity as well as many tumours, in particular in non-small cell lung cancer [16].”
BackgroundA small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“Here, a library of *150 to 200 selected kinases are expressed as phage particle fusion proteins and the binding affinity of kinase inhibitors is inferred by competition assays [9,10].”
BackgroundOverriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796 · cited 2×
“Of these second generation inhibitors, dasatinib (Sprycel, BMS-354825, Bristol-Myers Squibb) has been approved for the treatment of adults with CML and BCR-ABL-positive acute lymphoblastic leukemia with imatinib resistance or intolerance to previous therapy [5].”
BackgroundCharacterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492 · cited 2×
“imatinib-resistant forms with the exception of the T315I (gatekeeper) mutation [5,6].”
BackgroundThe development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors
Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1328 · Cited by 1,034
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879 · cited 2×
“Therefore, BCR-ABL is a suitable drug target, and research on this kinase cumulated in the discovery of imatinib (Gleevec1, STI-571), which is currently frontline therapy in CML. Imatinib is a relatively weak inhibitor of BCRABL with an IC50 in the upper nano-molar range, but has remarkable specificity, targeting only…”
BackgroundSelf-citationRix, U., Hantschel, O., Dürnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., et al. (2007) · Blood · doi:10.1182/blood-2007-07-102061 · Cited by 671
Self-citationInhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W. H., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 554 · cited 2×
“Also in the case of dasatinib, kinases such as the ABL and SRC had been already confirmed and more had been postulated to be potential targets [9].”
Background
Research works printed but not linked: 1
- le Coutre P, Blood
Cited by
Items 101–200 of 286
van Outersterp, I., Tasian, S. K., Reichert, C. E. J., Boeree, A., de Groot‐Kruseman, H. A., Escherich, G., Boer, J. M., & den Boer, M. L. (2024) · Blood · doi:10.1182/blood.2023023120 · Cited by 27
Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer
Choi, K., Cho, E., Bang, G., Lee, S.-J., Kim, B., Kim, J. H., Park, S., Han, E. H., Chung, Y., Kim, J. Y., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239276 · Cited by 27
“The majority of dasatinib target kinases identified in both dasatinib-sensitive and -resistant GC cells were reportedly dasatinib targets, which include ABL, SRC family kinases (SRC, LCK), and receptor tyrosine kinases (EGFR, EPHA2) [18,19].”
BackgroundHoffman, M. A., Fang, B., Haura, E. B., Rix, U., & Koomen, J. M. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00329 · Cited by 28
Self-citationRajala, H. L. M., Missiry, M. E., Ruusila, A., Koskenvesa, P., Brümmendorf, T. H., Gjertsen, B. T., Janssen, J. J. W. M., Lotfi, K., Markevärn, B., Olsson‐Strömberg, U., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2378-6 · Cited by 26
“In addition to their main target BCR-ABL1, all available TKIs also inhibit several other kinases, which are important for the function of the immune system (Hantschel et al. 2008).”
BackgroundMonobodies as possible next-generation protein therapeutics – a perspective
Hantschel, O. D. (2017) · Swiss Medical Weekly · doi:10.4414/smw.2017.14545 · Cited by 26
“This lack of selectivity results in doselimiting adverse events that decrease therapeutic efficacy [8].”
BackgroundSelf-citationOptimizing Combination Therapies with Existing and Future CML Drugs
Katouli, A. A., & Komarova, N. L. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012300 · Cited by 25
“Drugs in different combinations and different concentrations have been used in in vitro experiments to uncover the principles of resistance [21–26] and to suggest ways to avoid it.”
BackgroundThe Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling
Pankova, V., Thway, K., Jones, R. L., & Huang, P. H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.763640 · Cited by 25
“Tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib and dasatinib, are known to have a broad specificity and target multiple tyrosine kinases, including DDRs (Hantschel et al., 2008).”
BackgroundShort, N. J., Kantarjian, H. M., Pui, C., Goldstone, A. H., & Jabbour, E. J. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.05.015 · Cited by 24
“Imatinib Lee et al(38) 87 41 (16-71) Intensive chemotherapy 66% (at remission) 68% 39% (5-year) 33% (5-year) Yanada et al(39) 80 48 (15-63) Intensive chemotherapy 50% (day 63) 49% e 76% (1-year) Vignetti et al(40) 29 69 (61-83) Corticosteroids 4% e 48% (1-year) 74% (1-year) Bassan et al(41) 59 45 (20-66) Intensive che…”
Tyrosine phosphorylation of WIP releases bound WASP and impairs podosome assembly in macrophages
Vijayakumar, V., Monypenny, J., Chen, X. J., Machesky, L. M., Lilla, S., Thrasher, A. J., Antón, I. M., Calle, Y., & Jones, G. E. (2014) · Journal of Cell Science · doi:10.1242/jcs.154880 · Cited by 24
“Similarly, although Dasatinib primarily blocks c-Abl and Src kinases, it can also block Btk (Hantschel et al., 2008).”
BackgroundRosti, G., Castagnetti, F., Gugliotta, G., Palandri, F., & Baccarani, M. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.002 · Cited by 23
Harb, J. G., Neviani, P., Chyla, B., Ellis, J. J., Ferenchak, G. J., Oaks, J. J., Walker, C. J., Hokland, P., Roy, D.-C., Caligiuri, M. A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.151 · Cited by 23
Giansanti, P., Preisinger, C., Huber, K., Gridling, M., Superti‐Furga, G., Bennett, K. L., & Heck, A. J. R. (2014) · ACS Chemical Biology · doi:10.1021/cb500116c · Cited by 23
Self-citationNovel Therapies in Acute Lymphoblastic Leukemia
Faderl, S. H., & Kantarjian, H. M. (2007) · Springer eBooks · doi:10.1007/978-3-540-72304-2_19 · Cited by 22
Intermolecular Interactions in Crystal Structures of Imatinib-Containing Compounds
Vologzhanina, A. V., Ushakov, I. E., & Korlyukov, A. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238970 · Cited by 22
“The first therapeutic agent to treat CML through inhibition of fusion is imatinib [4,5] (Ima, commercially available as Gleevec, Scheme 1), which acts against a very limited set of tyrosine kinases [6] and some transmembrane transporters [7].”
BackgroundSun, J., Mohlin, S., Lundby, A., Kazi, J. U., Hellman, U., Påhlman, S., Olsen, J. V., & Rönnstrand, L. (2013) · Oncogene · doi:10.1038/onc.2013.479 · Cited by 21
Jo, T., Noguchi, K., Hayashi, S., Irie, S., Hayase, R., Shioya, H., Kaneko, Y., Horio, K., & Taguchi, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.7720 · Cited by 20
“All three TKIs (imatinib, dasatinib, and nilotinib) can inhibit not only BCR-ABL but also other tyrosine kinases, such as KIT, PDGFR, and SRC (4).”
BackgroundSarcoma Metabolomics: Current Horizons and Future Perspectives
Esperança‐Martins, M., Fernandes, I., do Brito, J. S., Macedo, D., Vasques, H., Serafim, T. L., Costa, L., & Dias, S. (2021) · Cells · doi:10.3390/cells10061432 · Cited by 20
“The main molecule targeting BCR-ABL tyrosine kinase domain is imatinib, but other tyrosine kinases inhibitors are available, as dasatinib [76] (Table 2).”
BackgroundHalbach, S., Rigbolt, K. T. G., Wöhrle, F. U., Diedrich, B., Gretzmeier, C., Brummer, T., & Dengjel, J. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-30 · Cited by 19
“However, given the fact that DST targets a broader spectrum of kinases than IM [37,44], including Src-family kinases that drive”
BackgroundEvaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay
Rohe, A., Göllner, C., Wichapong, K., Erdmann, F., Al-Mazaideh, G. M., Sippl, W., & Schmidt, M. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.06.007 · Cited by 19
Chimeric RNA in Cancer and Stem Cell Differentiation
Elfman, J., & Li, H. (2018) · Stem Cells International · doi:10.1155/2018/3178789 · Cited by 19
“As a result, patients diagnosed within the BCR-ABL1 subtype have favorable prognoses [15, 16, 18].”
BackgroundIizuka, K., Niwa, H., Kato, T., & Takeda, J. (2016) · BMJ Case Reports · doi:10.1136/bcr-2015-214284 · Cited by 19
DeAngelo, D. J., & Attar, E. C. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428190903518295 · Cited by 19
“against ABL, c-KIT, and platelet-derived growth factor-receptor (PDGFR), acting by competitive inhibition of adenosine triphosphate binding to the constitutively active BCR-ABL tyrosine kinase [6,7] thus impeding the growth and proliferation of the malignant cells and thereby permitting resumption of normal hematopoie…”
BackgroundImproved Angiostatic Activity of Dasatinib by Modulation with Hydrophobic Chains
Păunescu, E., Clavel, C. M., Nowak-Sliwinska, P. M., Griffioen, A. W., & Dyson, P. J. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500496u · Cited by 18
Fullmer, A., Kantarjian, H. M., Cortes, J. E., & Jabbour, E. J. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.546917 · Cited by 18
Mian, A. A., Metodieva, A., Badura, S., Khateb, M., Ruimi, N., Najajreh, Y., Ottmann, O. G., Mahajna, J. A., & Ruthardt, M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-411 · Cited by 18
“The stronger effects may be attributed to the fact that Dasatinib, originally developed as a SRC-kinase inhibitor, not only inhibits the BCR/ABL kinase but also targets a broader range of kinases compared to Nilotinib, the spectrum of which is mainly limited to ABL, c-KIT and PDGFR [16].”
BackgroundSeiter, K. P., Latrémouille-Viau, D., Guérin, A., Ndife, B. C., Habucky, K., Tang, D. H., Pivneva, I., Gagnon‐Sanschagrin, P., & Joseph, G. J. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0772-3 · Cited by 18
Messina, M., Chiaretti, S., Tavolaro, S., Peragine, N., Vitale, A., Elia, L., Sica, S., Levis, A., Guarini, A. R., & Foà, R. (2010) · Cancer · doi:10.1002/cncr.25113 · Cited by 17
“B-Lineage ALL BCR/ABL 40 21/19 47 (18-73) 88 (80-100)”
Sylvester, J. E., & Kron, S. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0157 · Cited by 17
“Profiling substrate response with the multitarget inhibitor dasatinib revealed characteristic inhibition patterns and reflected previously published observations (48).”
BackgroundMuñoz-Galván, S., Rivero, M., Peinado-Serrano, J., Martínez‐Pérez, J., Fernández-Fernández, M., Ortiz, M. J., García-Heredia, J. M., & Carnero, A. (2020) · Cells · doi:10.3390/cells9051071 · Cited by 17
“Dasatinib inhibits a broad spectrum of kinases, including Kit, PDGFR, FGFR1 and many others, although it is relatively specific for the Src and Abl family kinases such as Fyn, Yes, Src, and Lyk [59].”
BackgroundRapid Screening of Novel Agents for Combination Therapy in Sarcomas
Cubitt, C. L., Menth, J., Dawson, J. L., Martinez, G. V., Foroutan, P., Morse, D. L., Bui, M. M., Letson, G. D., Sullivan, D. M., & Reed, D. R. (2013) · Sarcoma · doi:10.1155/2013/365723 · Cited by 17
Colavita, I., Esposito, N., Martinelli, R., Catanzano, F., Melo, J. V., Pane, F., Ruoppolo, M., & Salvatore, F. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.04.009 · Cited by 17
Chen, G., Chen, W., Jin-hong, X., Ma, G., Hu, X., & Chen, G. (2023) · Journal of Future Foods · doi:10.1016/j.jfutfo.2023.03.003 · Cited by 16
Jalkanen, S. E., Vakkila, J., Kreutzman, A. S., Nieminen, J. K., Porkka, K., & Mustjoki, S. M. (2010) · Experimental Hematology · doi:10.1016/j.exphem.2010.09.005 · Cited by 16
Fang, B., Haura, E. B., Smalley, K. S. M., Eschrich, S. A., & Koomen, J. M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.03.027 · Cited by 16
Schneider, M., Korzeniewski, N., Merkle, K., Schüler, J. B., Grüllich, C., Hadaschik, B. A., Hohenfellner, M., & Duensing, S. M. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.06.001 · Cited by 16
“Dasatinib belongs to a class of TKI that also includes imatinib and nilotinib [5].”
BackgroundHanaizi, Z., Unkrig, C., Enzmann, H. G., Camarero, J., Sancho-López, A., Salmonson, T., Gisselbrecht, C., Laane, E., & Pignatti, F. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0294 · Cited by 16
Kinase-templated abiotic reaction
Saarbach, J., Lindberg, E., Folliet, S., Georgeon, S., Hantschel, O. D., & Winssinger, N. (2017) · Chemical Science · doi:10.1039/c7sc01416c · Cited by 16
Self-citationAdvances and Challenges in Targeted Therapy and Its Combination Strategies for Leukemia
Zhong, Z., Yao, R., Duan, Y., Ouyang, C., Du, Z., Li, L., Zou, H., Liu, Y., Xue, H., Li, L., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13071652 · Cited by 15
“It can effectively address a wider range of mutation situations, such as the E255K and G250E mutations within the phosphate-binding loop of the ATP-binding pocket, playing a key role in transforming CML into a manageable disease [15].”
Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells
Massimino, M., Tirrò, E., Stella, S., Pennisi, M. S., Vitale, S. R., Puma, A., Romano, C., Gregorio, S. D., Romeo, M. A., Raimondo, F. D., et al. (2020) · In Vivo · doi:10.21873/invivo.11802 · Cited by 15
Hochhaus, A., Kim, D.-W., Cortes, J. E., Sasaki, K., Mauro, M. J., Hughes, T. P., Breccia, M., Talpaz, M., Minami, H., Goh, Y. T., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02578-7 · Cited by 14
Fujiwara, S., Shirato, Y., Ikeda, T., Kawaguchi, S., Toda, Y., Ito, S., Ochi, S., Nagayama, T., Mashima, K., Umino, K., et al. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2378-y · Cited by 14
“Like BTK, spleen tyrosine kinase (Syk) is also a key component of the B cell receptor signaling pathway and has been regarded as therapeutic target for the treatment of NHL. Syk inhibitors have shown some antilymphoma activity in B cell malignancies including FL [14] and are evaluated as combination regimens in clinic…”
BackgroundImatinib-induced irreversible interstitial lung disease: A case report
Zhang, P., Huang, J., Jin, F., Pan, J.-H., & Ouyang, G. (2019) · Medicine · doi:10.1097/md.0000000000014402 · Cited by 14
“Nilotinib is an analog of imatinib, and it can block BCR-ABL kinase with a 20-fold higher intensity.([6,8]) Nilotinib has been approved for use in patients with CML showing imatinib resistance or intolerance.”
Perona, A., Ros, M. P., Mills, A., Morreale, A., & Gago, F. (2020) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-020-00328-8 · Cited by 14
Rafiei, A., Mian, A. A., Döring, C., Metodieva, A., Oancea, C., Thalheimer, F. B., Hansmann, M. L., Ottmann, O. G., & Ruthardt, M. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005144 · Cited by 14
“The native ABL kinase is finely regulated in response to growth factors and other stimuli [11].”
BackgroundHäselbarth, L., Karow, A., Mentz, K., Böttcher, M., Roche-Lancaster, O., Krumbholz, M., Jitschin, R., Mougiakakos, D., & Metzler, M. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03361-8 · Cited by 13
“1 3 by a larger target spectrum but also by its increased binding affinity to its target kinases [5, 43].”
BackgroundBagchee‐Clark, A. J., Mucaki, E. J., Whitehead, T., & Rogan, P. K. (2020) · MedComm · doi:10.1002/mco2.46 · Cited by 13
Mishall, K. M., Beadnell, T. C., Kuenzi, B. M., Klimczak, D. M., Superti‐Furga, G., Rix, U., & Schweppe, R. E. (2017) · Oncotarget · doi:10.18632/oncotarget.20488 · Cited by 13
“The DBKs provide a “proof of principle” for this approach, as many known targets of both drugs were identified, including Abl1/2, Src family kinases, and Eph family members [35].”
BackgroundSelf-citationZhang, X., Xu, N., Yang, Y., Lin, H., Liu, B., Du, X., Liu, X., Liang, R., Chen, C., Huang, J., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.02.008 · Cited by 12
Nerreter, T., Köchel, C., Jesper, D., Eichelbrönner, I., Putz, E., Einsele, H., & Seggewiß-Bernhardt, R. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.05.010 · Cited by 12
Kenchappa, R. S., Liu, Y., Argenziano, M., Banu, M. A., Mladek, A. C., West, R., Luu, A., Quiñones‐Hinojosa, A., Hambardzumyan, D., Justilien, V., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110054 · Cited by 12
“Consistent with this prediction, PKC ι -dependent Trp53 −/− GBM cells are highly sensitive to auranofin (Figure 4A) but relatively insensitive to saracatinib or dasatinib (Figures 6A and 6B), two SRC inhibitors (Hantschel et al., 2008; Hennequin et al., 2006).”
Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine
Samuel, Y., Babu, A., Karagkouni, F., Ismail, A., Choi, S., & Boussios, S. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45100526 · Cited by 12
“To overcome mutations and resistance, several second-generation TKIs have been developed and approved for clinical use, including nilotinib and dasatinib as first-or second-line treatments, and bosutinib as a second-line option [34].”
BackgroundNtari, L., Nikolaou, C., Kranidioti, K., Papadopoulou, D., Christodoulou‐Vafeiadou, E., Chouvardas, P., Meier, F. M. P., Geka, C., Denis, M. C., Karagianni, N., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02764-y · Cited by 12
“Dasatinib and bosutinib, two second-generation TKIs have been shown to display anti-inflammatory activities [13], sharing targets with imatinib and nilotinib [14], while also exhibiting their own target specificities [15].”
BackgroundLow c-Kit expression identifies primitive, therapy-resistant CML stem cells
Shah, M., Kumar, H., Qiu, S., Li, H., Harris, M., He, J., Abraham, A., Crossman, D. K., Paterson, A., Welner, R. S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.157421 · Cited by 11
“Several BCR-ABL–targeting TKIs, including imatinib, nilotinib, dasatinib, and ponatinib, have c-KIT–inhibitory activity in addition to ABL kinase–inhibitory activities (45).”
Joo, V., Petrovas, C., de Leval, L., Noto, A., Obéid, M., Fenwick, C. W., & Pantaleo, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213375 · Cited by 11
“Speci fi cally, the tyrosine kinase inhibitor dasatinib is known to have a wide range of targets beyond Bcr-abl including Src family kinases such as Fyn, FAK, and Lck as well as PDGF-R and c-KIT (60).”
Dasatinib promotes the activation of quiescent hematopoietic stem cells in mice
Duyvestyn, J. M., Taylor, S. J., Dagger, S. A., & Langdon, W. Y. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.02.008 · Cited by 11
Parry, N., Busch, C., Assmann, V. D., Cassels, J. E., Hair, A., Helgason, G. V., Wheadon, H., & Copland, M. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01211-1 · Cited by 11
“Nilotinib has a number of other kinase targets in addition to BCR::ABL1, including Abelson 1, KIT and platelet derived growth factor receptor [42], which results in apoptosis of healthy cells as well as BP-CML cells, although to a lesser degree.”
BackgroundJabbour, E. J., Fullmer, A., Cortes, J. E., & Kantarjian, H. M. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.s.001 · Cited by 11
“The instigating factor in the pathogenesis of chronic myeloid leukemia (CML) is the formation of the Philadelphia chromosome (Ph; 22q-) resulting from the reciprocal translocation between chromosomes 9 and 22 (t[9;22][q34;q11]), which is associated with the de novo creation of the BCR-ABL fusion oncogene.”
BackgroundUeda, N., Zhang, R., Tatsumi, M., Liu, T., Kitayama, S., Yasui, Y., Sugai, S., Iwama, T., Senju, S., Okada, S., et al. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2016.7 · Cited by 10
Sridevi, P., Nhiayi, M. K., Setten, R. L., & Wang, J. Y. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077495 · Cited by 10
“CML patients have been treated with daily dosing of imatinib for more than a decade, showing that the persistent inhibition of ABL kinase activity does not cause life-threatening side effects during adult life [40-42].”
BackgroundGeisler, K., Reischer, A., Kroeger, I., Jacobs, B., Meinhardt, K., Bauer, R., Ryffel, B., Mackensen, A., & Ullrich, E. (2014) · Oncology Reports · doi:10.3892/or.2014.3070 · Cited by 10
“Imatinib (STI-571, Glivec®, Gleevec®), the prototype of TKIs, was approved in 2003 for the first-line therapy of chronic myeloid leukemia (CML) (1).”
MethodInfluentialDao, K., Védy, D., López, J. L. G., Staneczek, O., Buclin, T., & Livio, F. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1250-3 · Cited by 10
“In the same way that nilotinib’s weaker inhibition of PDGFR-b (Platelet-Derived Growth Factor Receptor beta) may explain the lower incidence of fluid retention [9], different affinities for DDR (collagen receptor Discoidin Domain Receptor), a kinase that has been implicated in idiopathic pulmonary fibrosis, may explai…”
BackgroundJacobi, H., Vieri, M., Bütow, M., Namasu, C. Y., Flüter, L., Costa, I. G., Maié, T., Lindemann-Docter, K., Chatain, N., Beier, F., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1212392 · Cited by 9
Fatal myocardial infarction during nilotinib treatment in a 60-year-old male patient
Brauchli, Y. B., Wais, T., Gratwohl, A. A., Heim, D. A., Schipf, A., Diebold, J., & Krähenbühl, S. (2010) · Acta Oncologica · doi:10.3109/02841861003691952 · Cited by 9
Iraji, F., Moslehi, M., Namdar, F., Esmaeilifallah, M., Hejazi, S. H., Sokhanvari, F., Siadat, A. H., & Hosseini, S. (2019) · Advanced Biomedical Research · doi:10.4103/abr.abr_58_19 · Cited by 9
“Imatinib, as a multitarget inhibitor of C‐kit, PDGF‐R, and Abl/Arg kinases, is an oral anticancer drug approved for the treatment of CML and related cancers.[29] The therapeutic effects of imatinib have been attributed to its cell‐autonomous effects on tumor cells expressing oncogenic kinases or to its inhibition of c…”
BackgroundProtein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Perturbed Signaling and Role of Posttranslational Modifications in Cancer Drug Resistance
Aggarwal, S., Kandpal, M., Asthana, S., & Yadav, A. K. (2017) · Springer eBooks · doi:10.1007/978-3-319-48683-3_22 · Cited by 8
Mukhopadhyay, C., Triplett, A. A., Bargar, T. W., Heckman, C. A., Wagner, K., & Naramura, M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615677113 · Cited by 8
“Potential dasatinib targets include receptor tyrosine kinases, such as c-Kit, PDGFR, the ErbB family and ephrin receptors, and nonreceptor tyrosine kinases, such as the TEC family, FAK and Syk, as well as serine/threonine kinases in the MAP kinase pathways (39).”
BackgroundCo-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer
Rubio-Cuesta, B., Carretero-Puche, C., Llamas, P., Sarmentero, J., Gil-Calderon, B., Lens-Pardo, A., Antón-Pascual, B., Rubio-González, E., Cámara-Jurado, M., Salamanca, J., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03058-6 · Cited by 7
Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma
Ren, J. P., Amoozgar, Z., Uccello, T. P., Lei, P., Zhao, Y., Ho, W. W., Huang, P., Kardian, A., Mack, S. C., Duda, D. G., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2319474122 · Cited by 7
Arrington, J. V., Xue, L., Wang, W., Geahlen, R. L., & Tao, W. A. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00942 · Cited by 7
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
Kauer, J., Märklin, M., Pflügler, M., Hörner, S., Hinterleitner, C., Tandler, C., Jung, G., Salih, H. R., & Heitmann, J. S. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04039-5 · Cited by 7
“One example constitutes the affection of other kinases like the stem cell factor receptor (cKIT), Src kinases or platelet-derived growth factor receptors (PDGFR), which are involved in the activation of immune effector cells (Mannaioni et al. 1997; Hantschel et al. 2008).”
BackgroundChai, B.-Y., Gong, F., Chen, Z., Li, Z.-X., & Zhang, B. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/1986962 · Cited by 7
“Drugs such as imatinib, nilotinib, and dasatinib inhibit the phosphorylation activity of BCR-ABL and activation of downstream molecules, thus limiting the growth of CML cells [4].”
BackgroundKılıç-Kurt, Z., İşgör, Y. G., & Ölgen, S. (2009) · Archiv der Pharmazie · doi:10.1002/ardp.200800216 · Cited by 7
Karabay, A. Z., Özkan, T., Koç, A., Hekmatshoar, Y., Gurkan‐Alp, A. S., & Sunguroğlu, A. (2023) · Toxicology in Vitro · doi:10.1016/j.tiv.2023.105754 · Cited by 6
Are off-target effects of imatinib the key to improving beta-cell function in diabetes?
Welsh, N. (2022) · Upsala Journal of Medical Sciences · doi:10.48101/ujms.v127.8841 · Cited by 6
“example, the quinone oxidoreductase-2 enzyme, the ATPsensitive K+ channel, and the V-ATPase (14, 19, 20).”
BackgroundPerdomo, M. N. S., Stuckey, R., González-Pérez, E., Sánchez-Sosa, S., Estupiñan-Cabrera, P., Lakhwani, S., Miguel, J. D. G. S., Soler, N. H., Gordillo, M., Brito, G. G., et al. (2024) · Hematology Reports · doi:10.3390/hematolrep16010015 · Cited by 6
“Each approved TKI has a unique off-target spectrum, meaning that physicians should consider patient comorbidities in order to choose the most appropriate treatment [11,12].”
BackgroundSustained dasatinib treatment prevents early fibrotic changes following ocular trauma
Ueda, S., Nunn, B. M., Chauhan, R., McDonald, K., Kaplan, H. J., O’Toole, M. G., & Tamiya, S. (2021) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-05037-4 · Cited by 6
Nguyen, T. T. T., Tamai, M., Harama, D., Kagami, K., Kasai, S., Watanabe, A., Akahane, K., Goi, K., & Inukai, T. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03369-x · Cited by 6
“In contrast, imatinib and nilotinib are not potent Scr inhibitor [39, 40].”
BackgroundInclusion body myositis triggerred with long-term imatinib use
Deniz, R., Güzelbey, T., Narinoğlu, S., Kalem, G. Ş., Ekmen, Ş. A., Ünverengil, G., & Karaali, Z. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231168563 · Cited by 6
Candel, A. M., Cobos, E. S., Conejero‐Lara, F., & Martínez, J. C. (2009) · Protein Engineering Design and Selection · doi:10.1093/protein/gzp041 · Cited by 6
Quintás‐Cardama, A., Kim, T. D., Cataldo, V. D., & le Coutre, P. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-01222-8_8 · Cited by 6
Chahal, K. K., Li, J., Kufareva, I., Parle, M., Durden, D. L., Wechsler‐Reya, R. J., Chen, C. C., & Abagyan, R. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214901 · Cited by 6
“The analysis of two binding cavities (ANTA XV bound to SMO - PDB 4QIM and Nilotinib bound to ABL1 – PDB 3CS9) indicated that the overall shape and composition of both pockets were similar (elongated narrow channels with a large number of polar features, Figure 3), but the geometric details and specific arrangement of…”
BackgroundInfluentialImpaired Wound Healing with Imatinib Mesylate Therapy
Ronicke, M., & Erfurt-Berge, C. S. (2021) · Advances in Skin & Wound Care · doi:10.1097/01.asw.0000725176.48771.0f · Cited by 6
“Imatinib mesylate is a small molecule drug that inhibits a range of tyrosine kinases: (BCR-) Abelson tyrosine kinase (ABL), stem cell factor receptor (c-KIT), platelet-derived growth factor receptor (PDGFR), discoidin domain receptor tyrosine kinase 1, and the Nribosyldihydronicotinamide-quinone oxidoreductase.(9) Ind…”
BackgroundRókusz, A., Bugyik, E., Szabó, V., Szücs, A., Paku, S., Nagy, P., & Dezső, K. (2016) · International Journal of Experimental Pathology · doi:10.1111/iep.12209 · Cited by 5
“Imatinib, a small-molecule tyrosine kinase inhibitor, has been designed originally for the treatment of chronic myelogenous leukaemia, but it turned out to inhibit several tyrosine kinase receptors efficiently, including PDGFR (Hantschel et al. 2008).”
BackgroundRohe, A., Göllner, C., Erdmann, F., Sippl, W., & Schmidt, M. (2014) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2014.926343 · Cited by 5
Elfman, J., Pham, L.-P., & Li, H. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.04.005 · Cited by 5
Schubert, C., Chatain, N., Braunschweig, T. A., Schemionek, M., Feldberg, K., Hoffmann, M., Dufva, O., Mustjoki, S. M., Brümmendorf, T. H., & Koschmieder, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16152 · Cited by 5
Paediatric‐type nodal follicular lymphoma in a child diagnosed with chronic myeloid leukaemia
Domínguez‐Pinilla, N., Martínez‐Zamorano, E., Campos‐Martín, Y., Algara, P., González‐Granado, L. I., Gómez, M. Z., & Villanueva, M. M. (2019) · British Journal of Haematology · doi:10.1111/bjh.16089 · Cited by 5
“Syk is included in the off-target profile of dasatinib (Hantschel et al., 2008); which suggests that dasatinib would have greater off-target activity in concurrent NHL and CML than imatinib.”
BackgroundThe Role of Structural Biology in Kinase Inhibitor Drug Discovery Success
Angiolini, M. (2020) · Wiley eBooks · doi:10.1002/9781118681121.ch16 · Cited by 5
Drug- and toxin-induced pulmonary arterial hypertension: Current state of the literature
Ramírez, R. L., Thomas, C. A., Anderson, R. J., Bernardo, R. J., Al‐Motarreb, A., Suwaidi, J. M. S. A., Zamanian, R. T., & Pérez, V. D. J. (2020) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2019.19 · Cited by 5
“The widespread inhibition profile of dasatinib (as well as bosutinib or ponatinib) include inhibition of receptor and non-receptor tyrosine kinases, and other types of protein kinases, such as the platelet-derived growth factor SRC; this wider inhibition profile is not seen with imatinib or nilotinib (65, 74).”
BackgroundJournal, B. S., Matti, B. F., & Hameed, R. Y. (2015) · Baghdad Science Journal · doi:10.21123/bsj.12.1.110-118 · Cited by 5
Radiofrequency EMF irradiation effects on pre-B lymphocytes undergoing somatic recombination
Ioniţă, E., Marcu, A., Temelie, M., Savu, D., Şerbănescu, M., & Ciubotaru, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-91790-3 · Cited by 5
Daniels, H. G., Knicely, B. G., Miller, A. K., Thompson, A. M., Plattner, R., & Goellner, E. M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.940073 · Cited by 4
Calpain Small Subunit Mediated Secretion of Galectin-3 Regulates Traction Stress
Jang, I., Menon, S., Indra, I., Basith, R., & Beningo, K. A. (2024) · Biomedicines · doi:10.3390/biomedicines12061247 · Cited by 4
“STI571 is also known to inhibit the Abelson-related gene (Arg, also known as Abl2), which is within the Abl family of non-receptor tyrosine kinases [64].”
BackgroundA network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia
Bica, V., Venafra, V., Massacci, G., Graziosi, S., Gualdi, S., Minnella, G., Sorà, F., Chiusolo, P., Brunetti, M. E., Napolitano, G., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02185-0 · Cited by 4
“To ensure the specificity of our findings, we thoroughly evaluated 13 reported imatinib off-target proteins based on three studies (Table S9) [39–41].”
Metastasis suppressor genes in clinical practice: are they druggable?
Gelman, I. H. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10135-w · Cited by 4
“Imatinib was an early drug developed to target the BCR/ABL fusion oncogene in most cases of chronic myelogenous leukemia, yet it has been shown to target other RTKs such as MET, PDGFR, and EGFR (ERBB1) [226].”
BackgroundChronic Myeloid Leukemia (CML)
Coveler, A. L., & Oehler, V. G. (2011) · Springer eBooks · doi:10.1007/978-1-60761-565-1_4 · Cited by 4
Detecting Differentially Co-expressed Genes for Drug Target Analysis
Gao, X., & Arodź, T. (2013) · Procedia Computer Science · doi:10.1016/j.procs.2013.05.306 · Cited by 4
Chronic myeloid leukemia: where do we stand, where can we go?
Lewandowski, K. C., & Lewandowski, J. (2022) · Acta Haematologica Polonica · doi:10.5603/ahp.a2022.0012 · Cited by 4
Abad, C. L. R., & Razonable, R. R. (2022) · Springer eBooks · doi:10.1007/978-3-031-11363-5_15 · Cited by 4
Metadata
- Authors
- Hantschel, O., Rix, U., & Superti-Furga, G.
- Affiliations
- Austrian Academy of Sciences (AT)
- Venue
- Leukemia & Lymphoma
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 49
- Issue
- 4
- Pages
- 615-619
- ISSN
- 1026-8022 (ISSN-L)
- 1042-8194
- 1029-2403
- OpenAlex
- W2034862875
- Cited by
- 256
- References
- 17
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 4 · 2023: 14 · 2022: 15 · 2021: 14 · 2020: 21 · 2019: 10 · 2018: 16 · 2017: 19 · 2016: 10 · 2015: 17 · 2014: 15 · 2013: 19 · 2012: 23
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Locations
- Leukemia & lymphoma/Leukemia and lymphoma (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- BCR-ABL tyrosine kinase inhibitors, imatinib, nilotinib, dasatinib, chronic myeloid leukemia, target specificity, imatinib resistance, second-generation tyrosine kinase inhibitors
- MeSH terms
- Imatinib Mesylate, Dasatinib, Benzamides, Humans, Piperazines, Pyrimidines, Thiazoles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Drug Delivery Systems, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.